<DOC>
	<DOCNO>NCT00249119</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety different dos risperidone ( antipsychotic medication ) compare fix 10-mg dose standard antipsychotic , haloperidol , patient chronic schizophrenia .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Compared With Haloperidol Patients With Chronic Schizophrenia</brief_title>
	<detailed_description>Chronic schizophrenia longer-term condition characterize lack drive , underactivity slowness , social withdrawal . As acute form schizophrenia , delusion hallucination common . This randomized , double-blind , parallel-group study evaluate effectiveness safety five dosage risperidone ( 1 , 4 , 8 , 12 , 16 mg per day ) compare fix dose standard antipsychotic , haloperidol ( 10 mg per day ) patient chronic schizophrenia . The study compose two phase : 1-week period , patient receive placebo current medication schizophrenia treatment stop , double-blind treatment phase . The dos study drug increase progressively first week double blind period remain constant next 7 week . The primary measure effectiveness percent patient show clinical improvement Positive Negative Syndrome Scale Schizophrenia ( PANSS ) average total PANSS score , baseline end double-blind treatment . The PANSS rating scale measure symptoms schizophrenia . Safety evaluation include incidence adverse event , result clinical laboratory test ( hematology , biochemistry , urinalysis , hormone level ) , plasma level risperidone , measurement vital sign body weight , physical examination electrocardiogram ( ECG ) finding , neurological examination , Extrapyramidal Symptoms Rating Scale ( ESRS ) , scale use measure effect antipsychotic medication motor function patient . The study hypothesis risperidone dose 4 , 8 , 12 , 16 mg/day effective risperidone 10 mg/day , measure clinical improvement PANSS average total score PANSS , patient chronic schizophrenia . Risperidone oral tablet , twice-daily , start 1 2 mg/day , increase gradually Week 1 ( except 1 mg/day group ) , 0.5 , 2 , 4 , 6 , 8 mg twice daily 7 week . Haloperidol oral tablet , twice-daily , start 2 mg/day , increase 5 mg twice daily Week 1 , 5 mg twice daily 7 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis chronic schizophrenic disorder , accord Diagnostic Statistical Manual Mental Diseases , 3rd edition ( DSMIIIR ) criteria total score PANSS study entry &gt; =60 &lt; =120 physical neurological examination ECG find clinical hematology , biochemistry , urinalysis test result within normal limit study entry patient must able hospitalize first 3 week study , possible . Patients mental disorder chronic schizophrenic disorder patient clinically significant organic neurologic disease woman pregnant breastfeeding , woman childbearing potential without adequate birth control measure patient epilepsy history alcohol drug abuse history within previous 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>chronic schizophrenia</keyword>
	<keyword>psychotic disorder</keyword>
	<keyword>risperidone</keyword>
	<keyword>antipsychotic agent</keyword>
</DOC>